Pharma companies press on in fight against drug resistance, yet lag in access to antibiotics.
The 2021 AMR Benchmark evaluates 17 companies with a major stake in the anti-infectives space, including large research-based companies and generic medicine manufacturers. By comparing how they perform across a set of 20 metrics, the Benchmark tracks the progress and gaps in their efforts to keep medicines and vaccines available, despite the rise of drug resistance.
Large R&D-based companies
Generic medicine manufacturers
Progress on limiting antibiotic waste in environment
More companies are setting and enforcing limits for antibacterial material that can be released in manufacturing wastewaters. Companies generally perform best at implementing these limits at their own factories. However, just 5.2% of third-party manufacturing sites are reported as compliant.
More companies require suppliers to set AMR limits
Companies generally perform best at setting and monitoring specific AMR-related environmental standards at their own manufacturing sites. For the first time, the Benchmark reports that three generic medicine companies now require suppliers also meet such standards.
Shionogi is first to publish the details of its antibacterial waste-management performance
Shionogi has published information on audit results covering wastewater management, solid-waste management and discharge limits. Its disclosure covers all antibacterial APIs and/or drug products produced at its site in Japan and at supplier sites.
How pharma companies manage antibacterial waste
Many factories around the world are involved in the production of antibacterials, with many based in India and China. If these manufacturing sites do not manage their waste appropriately, the discharge of wastewaters containing active pharmaceutical ingredients (APIs) into the environment can trigger resistance.